Biogen Inc. (Nasdaq: BIIB) has released its 2023 Corporate Responsibility Report, illustrating the company’s strides in adhering to ethical business practices for the betterment of all stakeholders. Christopher A. Viehbacher,…
Novartis to Acquire Mariana Oncology, Enhancing Radioligand Therapy Portfolio Novartis has announced its agreement to acquire Mariana Oncology, a biotechnology company headquartered in Watertown, Massachusetts, specializing in the development of…
Encouraging findings emerge from an interim analysis of the ECHO Phase III trial, indicating that AstraZeneca’s Calquence (acalabrutinib), when paired with standard-of-care chemoimmunotherapy—bendamustine and rituximab—achieved a significant improvement in progression-free…
Novo Nordisk’s Q1 2024 Performance Highlights Growth and Expansion Novo Nordisk, a global healthcare company focusing on diabetes and other serious chronic diseases, has reported robust financial results for the…
In January 2016, Elisa Glass began feeling fatigued and unsteady. As her symptoms worsened to include severe body aches and weakness reminiscent of painful charley horses, she sought help from…
WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industry, has released its financial results for the first quarter ending March 31,…
CVS Health Corporation (NYSE: CVS) unveiled its financial performance for the first quarter ending March 31, 2024, showcasing robust revenue growth alongside strategic adjustments to its annual guidance. First Quarter…
Amgen (NASDAQ: AMGN) has announced the unveiling of groundbreaking respiratory research at the American Thoracic Society (ATS) 2024 International Conference, scheduled from May 12 to May 22 in San Diego.…
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a…
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) have received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab…
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA…
AstraZeneca’s Truqap (capivasertib) combined with Faslodex (fulvestrant) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced or metastatic breast cancer…